☆ 4.8 Article

A H3K27M-targeted vaccine in adults with diffuse midline glioma

NATURE MEDICINE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors

Michael Kilian et al.

Summary: Cancer immunotherapy relies on the fitness of cytotoxic and helper T cell responses. Dysfunctional cytotoxic T cell states in the tumor microenvironment (TME) are a main cause of resistance to immuno-therapy. Intratumoral myeloid cells, especially blood-borne myeloids (bbm), drive T cell dysfunction in the TME. This study demonstrates that major histocompatibility complex class II (MHCII)-restricted antigen presentation on bbm is crucial for controlling brain tumor growth.

CANCER CELL (2023)

添加到收藏夹

Article Multidisciplinary Sciences

GD2-CART cell therapy for H3K27M-mutated diffuse midline gliomas

Robbie G. Majzner et al.

Summary: Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs) are lethal pediatric tumors of the central nervous system. GD2-directed chimeric antigen receptor (CAR) T cells show promising preclinical efficacy. Four patients with H3K27M-mutated DIPG or spinal cord DMG were treated with GD2-CAR T cells and showed clinical and radiographic improvement.

NATURE (2022)

添加到收藏夹

Review Oncology

The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age

Huy Gia Vuong et al.

Summary: This study found that H3.3 mutation is associated with shorter survival in pediatric patients and longer survival in adult patients with DMGs. Patient age is a factor modulating the prognosis of H3.1 and H3.3 K27M mutations in DMG patients.

JOURNAL OF NEURO-ONCOLOGY (2022)

添加到收藏夹

Article Genetics & Heredity

The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location

Ilon Liu et al.

Summary: By analyzing the single-cell transcriptomics, epigenomics, and spatial architectures of a comprehensive cohort of H3-K27M DMGs, this study reveals the heterogeneity of these mutations at different ages and midline locations. The findings also provide insights into the cell-intrinsic and -extrinsic features of these tumors in relation to age and anatomical location, which can be used for rational modeling and therapeutic interventions.

NATURE GENETICS (2022)

添加到收藏夹

Article Genetics & Heredity

K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas

Selin Jessa et al.

Summary: This study provides an integrated analysis of 116 tumors and shows that K27M-mutant gliomas maintain chromatin configuration consistent with the cell of origin. Different types of K27M-mutant gliomas have different cell origins and molecular profiles.

NATURE GENETICS (2022)

添加到收藏夹

Article Oncology

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma

Lena Immisch et al.

Summary: The H3.3K27M mutation is unlikely to be a suitable target for cancer immunotherapy due to insufficient epitope processing and/or amount for recognition by HLA-A*02:01 restricted CD8(+) T cells.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Multidisciplinary Sciences

A vaccine targeting mutant IDH1 in newly diagnosed glioma

Michael Platten et al.

Summary: Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse glioma. The most common IDH1 mutation in gliomas affects codon 132 and encodes IDH1(R132H), which harbours a shared clonal neoepitope that is presented on major histocompatibility complex (MHC) class II. An IDH1(R132H)-specific peptide vaccine (IDH1-vac) induces specific therapeutic T helper cell responses that are effective against IDH1(R132H)+ tumours.

NATURE (2021)

添加到收藏夹

Review Oncology

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

David N. Louis et al.

Summary: The fifth edition of the WHO Classification of Tumors of the Central Nervous System integrates molecular diagnostics into CNS tumor classification, introduces different approaches to tumor nomenclature and grading, and emphasizes the importance of integrated diagnoses and layered reports.

NEURO-ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

David A. Reardon et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Mechanisms and therapeutic implications of hypermutation in gliomas

Mehdi Touat et al.

NATURE (2020)

添加到收藏夹

Article Oncology

Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience

Chantel Cacciotti et al.

JOURNAL OF NEURO-ONCOLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma

Sabine Mueller et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

添加到收藏夹

Article Oncology

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma

Stephanie L. Goff et al.

JOURNAL OF IMMUNOTHERAPY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

Naiara Martinez-Velez et al.

NATURE COMMUNICATIONS (2019)

添加到收藏夹

Article Clinical Neurology

Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas

Prerana Jha et al.

NEUROPATHOLOGY (2019)

添加到收藏夹

Article Oncology

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

Antonio Omuro et al.

NEURO-ONCOLOGY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells

Mara Vinci et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

Lukas Bunse et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Oncology

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Oncology

K27M-mutant histone-3 as a novel target for glioma immunotherapy

Katharina Ochs et al.

ONCOIMMUNOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Nicholas McGranahan et al.

SCIENCE (2016)

添加到收藏夹

Article Oncology

Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas

Martin J. van den Bent et al.

NEURO-ONCOLOGY (2015)

添加到收藏夹

Review Oncology

Diffuse intrinsic pontine glioma: a reassessment

Nathan J. Robison et al.

JOURNAL OF NEURO-ONCOLOGY (2014)

添加到收藏夹

Article Multidisciplinary Sciences

A vaccine targeting mutant IDH1 induces antitumour immunity

Theresa Schumacher et al.

NATURE (2014)

添加到收藏夹

Article Oncology

Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas

Sebastian Bender et al.

CANCER CELL (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Signatures of mutational processes in human cancer

Ludmil B. Alexandrov et al.

NATURE (2013)

添加到收藏夹

Article Oncology

Thalamic high-grade gliomas in children: a distinct clinical subset?

Christof M. Kramm et al.

NEURO-ONCOLOGY (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.